There is a very recent report from the Breast Cancer International Research Group (BCIRG) 006 trial[37] and an additional retrospective analysis of almost 5,000 patients[13] regarding the efficacy of trastuzumab in breast cancer patients with HER2 and TOP2A co-amplification. Here, TOP2A is linked to breast carcinoma.